Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation Associated with Cataract Surgery
Alcon benefits from leadership positions across eye care.
The stocks mentioned in this article be holdings in the managed portfolios of Validea Capital Management, a separate asset management firm founded by Validea.com founder John Reese. Validea Capital Management, which an SEC registered investment advisory firm and a separate company from Validea.com, ...
Four offerings deemed to be right for right now.
The company's diverse operating divisions and robust pipeline should lead to steady growth.
BBH Core Select manager Tim Hartch says focusing on easy-to-understand businesses, particularly in the financials and consumer defensive sectors, helps his team avoid negative surprises.